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Patient teachingAbstract Scientific knowledge has advanced to enable the development of inhaled insulin. It is a
form of diabetes medication administered via the pulmonary system that studies have shown to
be efficacious in the treatment of both type 1 and type 2 diabetes. Inhaled insulin is a new, safe
means to deliver insulin that may increase patient compliance with insulin therapy, helping them
to achieve optimal glycemic control and possibly reducing their risk of developing cardiovascular
complications. However, diabetes is a chronic illness requiring lifetime intervention. Empowering
patients with the knowledge of the diabetes disease process may give them the confidence to be more
autonomous in managing their diabetes. HIIP gives nurse practitioners a new option that may
improve their patients’ acceptance of insulin therapy, and improve glycemic control.
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The discovery of insulin in the early 1920 s was considered a
milestone in modern medicine, and for good reason. It was a
life-saving measure for those with type 1 diabetes. In type 2
diabetes, quality of life also took a quantum leap forward with
the use of insulin, and glucose control was now a more realistic
expectation [1]. The world heralded the discovery of insulin as
the ‘‘miracle cure” for diabetes that had been sought for years.
Insulin therapy has evolved since its inception. Initially, we
saw improvements in its purity, as well as new formulations
to increase action time and decrease frequency of injections.
With time, and a further understanding of the need to replace
insulin in a manner that mimicked normal physiology, newer
insulin was designed that could accomplish this goal more
effectively. Concurrently, methods of insulin delivery have also
improved, including disposable syringes, insulin pens, and
insulin pumps, all of which have helped to make insulin admin-
istration more reasonable and more comfortable [2].
Scientific knowledge has advanced to enable the develop-
ment of inhaled insulin [3]. It is a form of diabetes medication
administered via the pulmonary system that studies have
shown to be efficacious in the treatment of both type 1 and
type 2 diabetes. Approximately 80 years have been devoted
to the modification, purification, and production of human
inhaled insulin. The concept of inhaled insulin was first inves-
tigated in Germany in 1925 where the use of a nebulizer to deli-
ver insulin was initially explored [4,1]. Insulin is a protein
macromolecule with a large particle size that is not easily
absorbed into the alveoli of the lung. Many years of research
resulting in failures to achieve hypoglycemia with intrapul-
monary insulin delivery were likely due to under dosage, prob-
ably arising from the loss of drug in the oropharynx or in the
delivery device, secondary to large particle size. Since that
time, investigators have continued to focus on the development
of non-invasive routes to deliver proteins such as insulin.
Non-invasive routes include transdermal, oral, intranasal and
intrapulmonary [5]. While the nasal cavity is more accessible,
it has a decreased surface area for absorption compared to that
of the alveolar region of the lung. Intranasal insulin could also
be rapidly moved to the back of the nasopharynx by the
mucociliary mechanisms in the nose, and swallowed [6,3].
Insulin deposited in the lungs has a longer residence time
because mucociliary clearance mechanisms are minimal.
Transdermal and oral delivery routes face more challenges
due to poor absorption, but continue to be a focus of research.
There is currently one FDA approved HIIP that entered the
market in late 2006, and at least 6 new pulmonary insulin
drugs and delivery systems that are in active development.
HIIP gives nurse practitioners a new option that may improvetheir patients’ acceptance of insulin therapy, and improve
glycemic control [7].
Physiology of inhaling insulin
The inhalation of insulin into the lungs offers a new method of
insulin treatment delivery for people with diabetes. The same
features that make the lung so well suited for gas exchange also
make it an ideal organ for absorption of small molecules into
the bloodstream. The pulmonary alveolar surface area of the
lung is 130 m2, the size of a tennis court, and the pulmonary
capillary surface area is nearly as large at 115 m2. With each
breath, air flows into nearly 300 million alveoli. Moreover,
the alveolar lining cell is just 1–2 cm2 from the pulmonary cap-
illary lumen, a distance that favors rapid uptake into the
bloodstream [8].
Absorption of a molecule across the alveolar-capillary
interface is inversely related to its molecular mass. Small pep-
tides, such as insulin (approximately 6000 Da) are readily
absorbed across the very thin, vesiculated, permeable mem-
brane. Molecules that make it to the alveolar level have longer
residence time there, because mucociliary mechanisms at this
level are minimal (Fig. 1) [3].
There are several factors affecting lower respiratory deposi-
tion of an aerosol or dry powder formulation. One of these is
particle size. Particles greater than 5 cm2 in diameter impact
and are deposited in the pharynx and large airways. Particles
1–3 cm2 generally reach the lower airways and alveoli. Particle
velocity also affects deposition. Flow rates >35 L/min or
<10 L/min will favor upper airway impaction, while flow rates
of 15–25 L/min are ideal for lower airway deposition. Even under
the best of circumstances, however, only the minority of an aero-
sol or dry powder usually makes it deep into the lungs [9].Place of inhaled insulin in diabetes therapy
Insulin-dependent type1 or type2 diabetic patients are heavily
dependent on accurate dosing and tight glycemic control to
prevent acute, potentially severe hyperglycemia. Since studies
based on the ‘‘superiority” principle were only performed in
comparison with oral anti-hyperglycemic agents, there is no
clear advantage to replacing traditional insulin delivery sys-
tems with inhaled insulin. However, those patients treated with
several oral agents with fair-to-poor control and who are resis-
tant to the idea of injection treatment are excellent candidates
for inhaled human insulin [10]. Improved glycemic control in
type 2 diabetics could be achieved at an earlier stage, when oral
anti-hyperglycemic agents and inhaled human insulin combi-
nation therapy is considered as a bridge to converting to
Figure 1 Mechanism of insulin inhalation distribution through bronchial anatomy.
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absorption and nonadherent insulin-dependent patients may
also benefit from inhaled human insulin use [11]. Potential can-
didates need to be screened for pre-existing airways disease or
smoking history, and they need to be closely monitored for
appropriate glycemic control until further clinical experience
is attained. Patients also need extensive education on the lim-
itations of the formulation, so that inhaled human insulin is
avoided during states of potentially altered absorption (acute
bronchitis or bronchodilator use) [12,3].
Factors affecting inhaled insulin absorption
Smoking
Insulin absorption studies have looked at the maximum con-
centration of serum insulin after a dose of insulin (Cmax) as
well as the area under the serum insulin vs. time curve
(AUC) following that dose. Such studies have shown that
active smoking increases absorption of inhaled insulin 2- to
5-fold. The mechanism by which smoking affects inhaled insu-
lin absorption is still unknown [13]. The absorption of subcu-
taneous insulin is not affected by smoking. Cessation of
smoking is accompanied by a reduction in absorption of
inhaled insulin toward normal in as little as days. After a week
of abstinence from smoking, inhaled insulin absorption
decreases toward normal by as much as 50%. Resumption of
smoking for just 3 days increases absorption of the peptide
toward levels seen during chronic smoking. Because of thewide variations in absorption of inhaled insulin observed with
smoking, cigarette smoking within the past 6 months has been
a contraindication to inhaled insulin use in Phase 2 and 3 stud-
ies, and remains a contraindication to the use of inhaled insulin
[14,5,9]. Passive smoking has been examined experimentally, in
a study in which subjects were exposed to smoke in a smoking
chamber for 2 h at concentrations mimicking those found in a
smoky bar. Contrary to active smoking, passive smoking
appears to decrease inhaled insulin absorption by as much as
20–30%. It is not clear how long this effect lasts after subjects
are removed from the smoky environment. It is likewise
unclear why passive smoking and active smoking have
opposite effects on the absorption of inhaled insulin [15].
Asthma, chronic obstructive pulmonary disease, and their
treatment
Studies have shown that insulin absorption, as measured by
area under the curve (AUC) and maximum concentration
(Cmax), is 20–50% lower in mild to moderate asthmatics than
in normal patients. In patients with mild (FEV180% or more)
or moderate (FEV180% or less) asthma, the administration of
albuterol 30 min before taking inhaled insulin resulted in a 25–
50% increase in systemic insulin absorption compared with
administration of inhaled insulin alone. (Data on file) Inhaled
fluticasone appears to have no effect on inhaled insulin absorp-
tion, but other medications used for asthma and COPD have
not been systematically studied [16,17,5].
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In clinical studies of Exubera (inhaled insulin product, Exu-
bera was approved by the U.S. Food and Drug Administration
in January 2006. Upon approval, Pfizer and market analysts
predicted that Exubera would be the first inhaled option for
people who needed to take insulin), episodes of viral upper
respiratory infection, laryngitis, and acute bronchitis had no
discernible effect in either direction on inhaled insulin absorp-
tion. There were not enough cases of pneumonia in phase 2/3
studies to be able to comment on the effects of a more severe
infection on inhaled insulin absorption [16,9].
Respiratory tract effects of inhaled insulin
Respiratory safety of inhaled insulin has been a concern for
several reasons [10]:
(1) It is a novel drug substance with novel excipients that is
being inhaled.
(2) Its administration is chronic.
(3) Insulin is a polypeptide with potential for immune
response in the lung.
(4) Insulin has growth-promoting properties.
Contraindications to the use of inhaled insulin
There are several patient populations for whom the use of
inhaled insulin is not recommended. Women who are pregnant
should not use it, and its use has not been approved for chil-
dren or adolescents. Current tobacco smokers or patients
who have smoked in the preceding six months are also not can-
didates for inhaled insulin. Smoking has been shown to
increase the rate and extent of inhaled insulin absorption
[18,19,10]. Smoking cessation, nicotine replacement therapy,
and acute smoking re-exposure are also associated with clini-
cally significant alterations in inhaled insulin pharmacokinetics
and glucodynamics [20,7]. Thus smokers or former smokers at
risk of recidivism should not use inhaled insulin. Patients with
compromised lung function, such as those with asthma or
chronic obstructive pulmonary disease (COPD), are also not
candidates for the inhaled insulin that is currently marketed,
due to unpredictable absorption rates and possible problems
with simultaneous use of bronchodilators. Insulin inhalation
was recently reported to be well tolerated by patients with
COPD, and to elicit time-exposure and time-action profiles
similar to subcutaneous insulin lispro (Insulin lispro is a
man-made product that is similar to human insulin. It replaces
the insulin that the body would normally make. Insulin lispro
starts working faster and lasts for a shorter time than regular
insulin. It works by helping blood sugar (glucose) get into cells
so the body can use it for energy. This medication is usually
used with a medium- or long-acting insulin product. Insulin lis-
pro may also be used with other oral diabetes medications
(such as sulfonylureas like glyburide or glipizide) [13]. How-
ever, there was reduced insulin absorption and decreased meta-
bolic effects when this population was compared with healthy
subjects. Clinical evaluations of the use of inhaled insulin in
these populations are ongoing [1,3].Patient preference for inhaled insulin therapy
Some of the reported barriers to strict glycemic control in
patients with diabetes include reluctance to initiate insulin
therapy and poor patient adherence because of pain and fear
of injection, inconvenience, and social stigma associated with
injections. Satisfaction surveys assessing the flexibility and ease
of use, pain, side effects, and social acceptance of inhaled insu-
lin have been overwhelmingly favorable [7,12]. In patients with
either T1DM or T2DM who have previously used subcuta-
neous insulin for diabetes management, 80% preferred inhaled
insulin over conventional subcutaneous insulin for their meal
time insulin therapy [4]. In a recent report of self-directed
versus intensive patient training for use of the Insulin Inhaler,
it was found that patients can be self-directed without
detrimental effects on metabolic [8] or patient-reported [20]
outcomes, including measures of vitality, diabetes associated
symptoms, fear of hypoglycemia, and insulin delivery system
satisfaction. These data support the Insulin Inhaler as a
patient-friendly insulin delivery method that should appeal
to both clinicians and patients. Importantly, this sufficiency
of patient-directed training should allow precious diabetes
education resources to be deployed in other important aspects
of diabetes care beyond teaching the mechanics of inhaled
insulin administration.
Patient teaching
Empowering patients with the knowledge of the diabetes dis-
ease process may give them the confidence to be more auton-
omous in managing their diabetes [8]. Teach patients about
all the treatment options and have appropriate literature for
them to read. The HIIP comes with a product information
insert that covers the proper use of the inhaler device and tech-
nique. Providers should be knowledgeable regarding the inha-
ler devices and teaching patients to use them correctly [11].
Patients should be instructed to inform their primary care pro-
vider of changes in their medication regimens. Patients should
be encouraged to develop a consistent meal planning and exer-
cise routine to improve glycemic control. Excessive carbohy-
drate intake or skipping meals may lead to hyperglycemia or
hypoglycemia, respectively. Alcohol can greatly affect blood
glucose levels [14,20].
Summary and conclusions
Diabetes is a significant worldwide health problem. Insulin
resistance and deregulated BG control are established risk fac-
tors for micro-vascular complications and cardiovascular dis-
ease, with risk reduced by adequate BG control and
intensive diabetes therapy. Despite the availability of a variety
of medications for BG regulation, most patients do not achieve
optimal BG control. Inhaled insulin is a new, safe means to
deliver insulin that may increase patient compliance with insu-
lin therapy, helping them to achieve optimal glycemic control
and possibly reducing their risk of developing cardiovascular
complications. However, diabetes is a chronic illness requiring
lifetime intervention. Thus, long term studies are still required
in order to ensure the continued efficacy and safety of this new
treatment for diabetes.
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